Orthofix Medical Inc. (OFIX) Gross Margin
- Gross margin · 12 months: Value 71.31%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 71.31% | Gross profit / revenue. Period ending 2026-06-30. $594.12M ÷ $833.19M × 100 ≈ 71.31% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 594.12M USD | Gross Profit |
| Revenue | 833.19M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 239.07M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $594.12M | $833.19M | $239.07M | 71.31% |
| 2026-03-31 | $583.94M | $825.37M | $241.43M | 70.75% |
| 2025-12-31 | $566.02M | $822.31M | $256.30M | 68.83% |
| 2025-09-30 | $558.52M | $818.06M | $259.54M | 68.27% |
| 2025-06-30 | $545.05M | $809.03M | $263.98M | 67.37% |
| 2025-03-31 | $540.26M | $804.53M | $264.27M | 67.15% |
| 2024-12-31 | $545.88M | $799.49M | $253.61M | 68.28% |
| 2024-09-30 | $533.67M | $784.25M | $250.57M | 68.05% |
| 2024-06-30 | $518.38M | $771.65M | $253.26M | 67.18% |
| 2024-03-31 | $503.19M | $760.04M | $256.86M | 66.20% |
| 2023-12-31 | $486.27M | $746.64M | $260.37M | 65.13% |
| 2023-09-30 | $438.82M | $668.46M | $229.64M | 65.65% |
| 2023-06-30 | $402.48M | $598.45M | $195.97M | 67.25% |
| 2023-03-31 | $369.40M | $529.50M | $160.10M | 69.76% |
| 2022-12-31 | $337.17M | $460.71M | $123.54M | 73.18% |
| 2022-09-30 | $339.80M | $463.55M | $123.75M | 73.30% |
| 2022-06-30 | $340.50M | $461.98M | $121.48M | 73.70% |
| 2022-03-31 | $347.99M | $465.30M | $117.32M | 74.79% |
| 2021-12-31 | $349.56M | $464.48M | $114.91M | 75.26% |
| 2021-09-30 | $346.30M | $457.03M | $110.73M | 75.77% |
| 2021-06-30 | $346.92M | $455.59M | $108.67M | 76.15% |
| 2021-03-31 | $302.94M | $407.33M | $104.39M | 74.37% |
| 2020-12-31 | $304.67M | $406.56M | $101.89M | 74.94% |
| 2020-09-30 | $311.43M | $410.44M | $99.01M | 75.88% |
| 2020-06-30 | $315.29M | $412.95M | $97.66M | 76.35% |
| 2020-03-31 | $355.36M | $455.67M | $100.31M | 77.99% |
| 2019-12-31 | $359.35M | $459.95M | $100.61M | 78.13% |
| 2019-09-30 | $359.50M | $459.54M | $100.04M | 78.23% |
| 2019-06-30 | $358.58M | $457.75M | $99.17M | 78.34% |
| 2019-03-31 | $357.26M | $453.44M | $96.19M | 78.79% |
| 2018-12-31 | $356.41M | $453.04M | $96.63M | 78.67% |
| 2018-09-30 | $354.30M | $448.86M | $94.56M | 78.93% |
| 2018-06-30 | $348.14M | $442.40M | $94.26M | 78.69% |
| 2018-03-31 | $345.19M | $439.79M | $94.60M | 78.49% |
| 2017-12-31 | $340.79M | $433.82M | $93.04M | 78.55% |
| 2017-09-30 | $332.67M | $425.46M | $92.80M | 78.19% |
| 2017-06-30 | $329.76M | $418.71M | $88.96M | 78.75% |
| 2017-03-31 | $325.55M | $413.85M | $88.30M | 78.66% |
| 2016-12-31 | $321.94M | $409.79M | $87.85M | 78.56% |
| 2016-09-30 | $319.93M | $405.87M | $85.94M | 78.82% |
| 2016-06-30 | $318.60M | $408.53M | $89.93M | 77.99% |
| 2016-03-31 | $316.08M | $405.41M | $89.32M | 77.97% |
| 2015-12-31 | $309.96M | $396.49M | $86.53M | 78.18% |
| 2015-09-30 | $305.58M | $392.15M | $86.57M | 77.92% |
| 2015-06-30 | $304.02M | $391.99M | $87.97M | 77.56% |
| 2015-03-31 | $300.55M | $392.02M | $91.48M | 76.67% |
| 2014-12-31 | $303.37M | $402.28M | $98.91M | 75.41% |
| 2014-09-30 | $296.30M | $407.82M | $111.58M | 72.66% |
| 2014-06-30 | $287.32M | $398.69M | $111.37M | 72.07% |
| 2014-03-31 | $299.19M | $398.50M | $99.31M | 75.08% |
| 2013-12-31 | $298.23M | $400.53M | $102.30M | 74.46% |
| 2013-09-30 | $317.03M | $411.76M | $94.73M | 76.99% |
| 2013-06-30 | $331.68M | $426.88M | $95.19M | 77.70% |
| 2013-03-31 | $359.28M | $446.53M | $87.25M | 80.46% |
| 2012-12-31 | $375.83M | $462.32M | $86.49M | 81.29% |
| 2012-09-30 | $444.44M | $582.24M | $137.79M | 76.33% |
| 2012-06-30 | $445.52M | $584.79M | $139.28M | 76.18% |
| 2012-03-31 | $444.26M | $582.96M | $138.71M | 76.21% |
| 2011-12-31 | $439.80M | $578.99M | $139.19M | 75.96% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | $432.33M | $564.71M | (m) | 76.56% |
| 2010-12-31 | $432.65M | $564.37M | $131.72M | 76.66% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $407.19M | $545.63M | $138.45M | 74.63% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |